Brain fog can feel like the most personal menopause symptom.
That makes testosterone sound tempting.
But the evidence has not caught up with the promise.
A 2024 retrospective pilot of 510 peri- and postmenopausal women reported improvement in mood and cognitive symptoms after 4 months of transdermal testosterone. Cognitive mean symptom scores decreased by 22%, and 39% of women reported cognitive improvement. [1]
That is a signal worth studying.
It is not a randomized treatment indication.
The strongest testosterone evidence is still low desire disorder
The major evidence base for testosterone in women is sexual desire, not cognition.
A 2019 systematic review and meta-analysis included 36 randomized trials and 8,480 participants. It found improvements in sexual function outcomes, but also androgenic side effects such as acne and hair growth. [2]
The 2019 Global Consensus Position Statement and the 2021 International Society for the Study of Women's Sexual Health guideline both keep the main evidence-supported indication narrow: systemic testosterone can be considered for postmenopausal women with hypoactive sexual desire disorder after assessment and monitoring. [3] [4]
That distinction protects the reader.
Low desire, low energy, mood, and brain fog can travel together, but they are not the same endpoint.
The evidence limits are the point: a cognitive symptom signal can be worth studying without becoming a cognitive treatment claim.
Evidence-limit table
| Claim | What the evidence says | Safer next step |
|---|---|---|
| "Testosterone treats brain fog." | A 510-woman retrospective pilot reported improvement, but it was not randomized. [1] | Treat it as a signal, not an indication. |
| "Low testosterone explains cognitive decline." | Older-women cohort data do not support a simple testosterone-cognition story. [5] [6] | Look for sleep, mood, medication, and metabolic causes. |
| "hypoactive sexual desire disorder evidence transfers to cognition." | The strongest randomized evidence is sexual-function evidence. [2] | Keep hypoactive sexual desire disorder and cognition as separate endpoints. |
| "More testosterone means clearer thinking." | Consensus guidance does not support optimization dosing. [3] [4] | Avoid supraphysiologic exposure and monitor side effects. |
Observational cognition studies do not show a simple testosterone answer
A 2025 prospective analysis followed 395 Australian women aged 70 and older. Thirty-nine percent had a decline in blood testosterone over 3 years. That decline was not associated with decline on the Modified Mini-Mental State Examination, Hopkins Verbal Learning Test immediate or delayed recall, Controlled Oral Word Association Test, or Symbol Digit Modalities Test. [5]
Another Australian study examined 5,511 women aged at least 70 years and found no associations between estrone, estradiol, testosterone, or dehydroepiandrosterone and cognitive performance. [6]
These women were older than the core 45-60 reader.
Still, the data argue against a simple claim that lower testosterone equals brain fog.
The pilot result should be read as a hypothesis
The 510-woman pilot is useful because it reflects a real clinic question: women on hormone replacement therapy with persistent low libido, cognitive symptoms, and negative mood symptoms. [1]
But it was retrospective. There was no placebo group, and the same 4-month window can include expectation effects, hormone replacement therapy adjustment, sleep changes, relationship changes, and regression to the mean. [1]
Even the authors concluded that randomized clinical trials are needed to establish long-term efficacy and safety for cognitive and psychological symptoms. [1]
That sentence should shape the clinical posture.
We can discuss the signal without converting it into a claim.
What a better brain-fog workup looks like
Brain fog after menopause is often a cluster problem.
Night sweats can fragment sleep. Sleep apnea becomes more common with weight and age. Depression and anxiety can impair concentration. Alcohol, antihistamines, sedatives, and some blood-pressure drugs can affect alertness. Thyroid disease, anemia, B12 deficiency, and glucose swings can mimic hormonal fog.
This is why testosterone should not be the first explanation.
If low desire is also present, a clinician can assess hypoactive sexual desire disorder and whether testosterone discussion fits the evidence boundary.
If cognitive symptoms are the main issue, the safer path is sleep, mood, medication, metabolic, and red-flag review first.
Who this fits
This article fits a woman who is hearing that testosterone might fix brain fog and wants the evidence boundary before making a treatment decision.
It does not fit as a reason to start testosterone for cognition alone. If low desire with distress is also present, the clinician can assess hypoactive sexual desire disorder separately. If cognition is the main concern, the better first move is to check sleep quality, hot flashes, mood, medications, alcohol, thyroid disease, anemia, B12, glucose swings, sleep apnea, and neurologic red flags.
Decision checkpoint: what changes the plan
| Signal | Why it changes the plan | What to do next |
|---|---|---|
| Low desire with distress after other causes are reviewed | Consensus guidance keeps the evidence-supported use narrow: postmenopausal hypoactive sexual desire disorder. | Confirm the diagnosis before discussing dose or route. |
| Fatigue, mood, brain fog, muscle, or anti-aging is the main goal | These are not the guideline-backed testosterone endpoints for women. | Look for sleep, mood, medication, thyroid, iron, pain, relationship, or metabolic drivers first. |
| Pellets, injections, male products, or compounded high-strength creams are proposed | Dose control and supraphysiologic exposure become central risks. | Ask how levels will stay in the female physiologic range. |
| Acne, hair growth, scalp shedding, voice change, clitoral changes, or mood changes appear | Androgen side effects can show up before benefit is clear. | Treat these as red flags for dose and monitoring review. |
| Breast cancer history, abnormal bleeding, liver disease, lipid concerns, or complex hormone therapy is present | The plan may need specialist input or a different route. | Review contraindications, monitoring, and alternatives before treatment. |
Evidence boundary
For testosterone for brain fog, the key testosterone boundary is the tempting shortcut: women do not need a smaller version of male TRT. Global consensus and International Society for the Study of Women's Sexual Health guidance, applied to cognitive symptoms, keep systemic testosterone focused on carefully assessed hypoactive sexual desire disorder in postmenopausal women, with physiologic dosing and monitoring rather than optimization language. [3] [4]
For the brain-fog question, the meta-analysis evidence supports sexual-function outcomes in appropriate populations, but it also reports androgenic adverse effects such as acne and unwanted hair growth and raises route-specific safety issues. That, for testosterone for brain fog, is why product form cannot be the headline. For cognitive symptoms, dose, level, side effects, symptom target, and stopping rules are the headline. [4]
With the brain-fog question, the negative space is just as important. For testosterone for brain fog, testosterone is not a default treatment for brain fog, fatigue, weight gain, mood, wrinkles, or normal aging. If those are the main complaints around cognitive symptoms, the first move is differential diagnosis, not dose selection.
What this changes at the visit
For the brain-fog question, bring the symptom target, level of distress, pain or dryness symptoms, mood and sleep history, medication list, relationship context if relevant, prior hormone use, baseline testosterone result if available, route being proposed, and any androgenic side effects. The clinician can then decide, for testosterone for brain fog, whether this is hypoactive sexual desire disorder evaluation, another sexual-pain/genitourinary syndrome of menopause pathway, or a non-testosterone workup.
What to ask a clinician
Ask:
- Are my cognitive symptoms more consistent with sleep disruption, mood, medication effects, anemia, thyroid disease, glucose swings, or sleep apnea?
- Is low desire with distress also present, or is cognition the main concern?
- If testosterone is discussed, what evidence endpoint are we treating?
- What side effects or levels would make the dose unsafe?
- What red flags would need neurologic or urgent evaluation instead of hormone treatment?
Bottom line
Testosterone may become part of future research for mood and cognitive symptoms after menopause.
Today, the more defensible statement is narrower.
There is a nonrandomized pilot signal. There are large observational analyses that do not support a simple testosterone-cognition story. The consensus-backed use remains postmenopausal hypoactive sexual desire disorder, not brain fog.
For a woman trying to get her mind back, that is not dismissal.
It is a better starting point.
Related reading:
- Testosterone for Fatigue After Menopause.
- Testosterone for Mood After Menopause.
- Testosterone for Women After Menopause Has One.
References
[1] Glynne S, Kamal A, Kamel AM, Reisel D, Newson L. Effect of transdermal testosterone therapy on mood and cognitive symptoms in peri- and postmenopausal women: a pilot study. Arch Womens Ment Health. 2025;28(3):541-550. doi:10.1007/s00737-024-01513-6 https://pubmed.ncbi.nlm.nih.gov/39283522/
[2] Islam RM, Bell RJ, Green S, Page MJ, Davis SR. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol. 2019;7(10):754-766. doi:10.1016/s2213-8587(19)30189-5 https://pubmed.ncbi.nlm.nih.gov/31353194/
[3] Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. Climacteric. 2019;22(5):429-434. doi:10.1080/13697137.2019.1637079 https://pubmed.ncbi.nlm.nih.gov/31474158/
[4] Parish SJ, Simon JA, Davis SR, et al. International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. J Sex Med. 2021;18(5):849-867. doi:10.1016/j.jsxm.2020.10.009 https://pubmed.ncbi.nlm.nih.gov/33814355/
[5] Sultana F, Islam RM, Davis SR. Associations between declining testosterone concentrations and cognitive performance in community-dwelling older Australian women: a prospective cohort study. Climacteric. 2026;29(1):46-52. doi:10.1080/13697137.2025.2539854 https://pubmed.ncbi.nlm.nih.gov/40810327/
[6] Sultana F, Davis SR, Murray AM, Woods RL, McNeil JJ, Islam RM. Sex hormones, SHBG and cognitive performance among older Australian women: an observational study. Climacteric. 2023;26(2):121-128. doi:10.1080/13697137.2023.2166824 https://pubmed.ncbi.nlm.nih.gov/36716780/